—
C+
C+ The full Closelook — membership. Open the C+ overview

Protagonist Therapeutics Inc (PTGX) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Protagonist Therapeutics Inc

PTGX in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Protagonist Therapeutics is a clinical-stage biotechnology company that designs peptide-based drugs meant to work like larger biologic molecules but taken as oral or injectable treatments. Its lead programmes include a treatment for the blood disorder polycythemia vera and an oral therapy for plaque psoriasis, alongside earlier work in obesity and skin and lung disease. It is based in Newark, California, and has no approved product generating sales yet.
Where it sits in the stack
Protagonist carries no seat in our index and sits outside the semiconductor build-out entirely; it belongs to the clinical-stage biotechnology sleeve of the diary's healthcare coverage, where value depends on trial results rather than shipped volume.
Who it is priced against
There is no peer group set for this name in our coverage; the comparison an investor would draw is with other clinical-stage biotech companies developing peptide or hormone-mimetic drugs for rare and immune conditions, a group that includes larger developers such as Amgen when a partnership or licensing deal is in view.
Why Closelook tracks it
It holds no index seat and is not quoted in the editions. It carries a Closelook score, but only one module has been scored so far, so the read is still being built.
What the diary watches
Whether trial results for its lead programmes, particularly the rare blood disorder treatment in late-stage testing, move the shares more than the broader index moves on any given day.

Protagonist Therapeutics Inc (PTGX) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for PTGX, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 2 analyst actions on the wire · latest: price target by BMO Capital, 2026-09-01

The Street on this name

Analyst actions and the latest print for PTGX from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target BMO Capital — target 190 from 178 Target raised to $190 from $178 (+28.6% to spot) 2026-09-01
  • Price target H.C. Wainwright — target 170 from 167 Target raised to $170 from $167 (+17.6% to spot) 2026-08-31

2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst wire → · Earnings wire →

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Protagonist Therapeutics Inc (PTGX)?

Protagonist Therapeutics Inc trades as PTGX on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is PTGX in a Closelook index?

Not currently — Protagonist Therapeutics Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does PTGX trade against its moving averages?

Uptrend stack intact: Trades +0.1% vs the 50-day and +32.6% vs the 200-day average, 10.6% below the 52-week high and +143.9% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Protagonist Therapeutics Inc do?

Protagonist Therapeutics is a clinical-stage biotechnology company that designs peptide-based drugs meant to work like larger biologic molecules but taken as oral or injectable treatments. Its lead programmes include a treatment for the blood disorder polycythemia vera and an oral therapy for plaque psoriasis, alongside earlier work in obesity and skin and lung disease. It is based in Newark, California, and has no approved product generating sales yet. There is no peer group set for this name in our coverage; the comparison an investor would draw is with other clinical-stage biotech companies developing peptide or hormone-mimetic drugs for rare and immune conditions, a group that includes larger developers such as Amgen when a partnership or licensing deal is in view.

Where does Protagonist Therapeutics Inc sit in the AI build-out?

Protagonist carries no seat in our index and sits outside the semiconductor build-out entirely; it belongs to the clinical-stage biotechnology sleeve of the diary's healthcare coverage, where value depends on trial results rather than shipped volume. It holds no index seat and is not quoted in the editions. It carries a Closelook score, but only one module has been scored so far, so the read is still being built.

What has Wall Street done on Protagonist Therapeutics Inc recently?

The most recent analyst action on Protagonist Therapeutics Inc on the Closelook wire is a price target by BMO Capital on 2026-09-01 (target 190 from 178). 2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for PTGX, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe